ixekizumab news

All news on ixekizumab (also known as Taltz): plants, production capacities, investments and involved companies.

28 March 2026

Lilly: Taltz + Zepbound superior to Taltz alone in psoriatic arthritis with obesity

Phase 3b TOGETHER‑PsA: combination therapy improved ACR50, MDA, fatigue, function, QoL and cardiometabolic markers; 36‑week primary endpoint met (ACR50+≥10% weight loss 31.7% vs 0.8%).

Who will be producing ixekizumab in the future?

Find out with chemXplore Alpha

Learn more